Education
About Us
Working with TipRanks
Follow Us
Avita Medical (RCEL)
NASDAQ:RCEL
RCEL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.60 - $14.16
Previous CloseN/A
Volume824.49K
Average Volume (3M)1.05M
Market Cap
$139.75M
Enterprise Value$168.38M
Total Cash (Recent Filing)$15.69M
Total Debt (Recent Filing)$44.59M
Price to Earnings (P/E)―
Beta1.97
Next Earnings
Nov 06, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.38
Shares Outstanding26,618,935
10 Day Avg. Volume2,473,738
30 Day Avg. Volume1,048,750
Financial Highlights & Ratios
PEG Ratio-0.08
Price to Book (P/B)73.64
Price to Sales (P/S)5.16
P/FCF Ratio-5.69
Enterprise Value/Market Cap1.20
Enterprise Value/Revenue2.25
Enterprise Value/Gross Profit2.67
Enterprise Value/Ebitda-3.77
Forecast
1Y Price Target
$8.80Price Target Upside67.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical SuccessA recent study demonstrated reduced length of hospital stay among burn patients treated with RECELL, with significant cost savings potential.
New Product LaunchPositive clinical updates on Avita's new dermal matrix offering, Cohealyx, support its recent commercial launch and expected revenue growth acceleration.
Product AdoptionRECELL's benefits have resulted in its adoption in more than 130 burn centers across the US, bolstering its competitive positioning.
Bears Say
Cash Flow ChallengesRCEL's limited cash on hand, current operating cash burn, need for additional capital, and limits on how many shares can be issued exacerbate the downside risk.
Financial PerformanceRCEL has reduced guidance in 5 of the last 7 quarters and missed top-line in the past 3 quarters.
Reimbursement IssuesReimbursement to providers via Medicare Administrative Contractors were not being paid despite submitting claims for usage.
Avita Medical News
RCEL FAQ
What was Avita Medical’s price range in the past 12 months?
Avita Medical lowest stock price was $3.60 and its highest was $14.16 in the past 12 months.
What is Avita Medical’s market cap?
Avita Medical’s market cap is $139.75M.
When is Avita Medical’s upcoming earnings report date?
Avita Medical’s upcoming earnings report date is Nov 06, 2025 which is in 41 days.
How were Avita Medical’s earnings last quarter?
Avita Medical released its earnings results on Aug 07, 2025. The company reported -$0.38 earnings per share for the quarter, missing the consensus estimate of -$0.25 by -$0.13.
Is Avita Medical overvalued?
According to Wall Street analysts Avita Medical’s price is currently Undervalued.
Does Avita Medical pay dividends?
Avita Medical does not currently pay dividends.
What is Avita Medical’s EPS estimate?
Avita Medical’s EPS estimate is -0.26.
How many shares outstanding does Avita Medical have?
Avita Medical has 26,618,935 shares outstanding.
What happened to Avita Medical’s price movement after its last earnings report?
Avita Medical reported an EPS of -$0.38 in its last earnings report, missing expectations of -$0.25. Following the earnings report the stock price went down -21.004%.
Which hedge fund is a major shareholder of Avita Medical?
Currently, no hedge funds are holding shares in RCEL
Avita Medical Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.80 (67.62% Upside)
$8.80 (67.62% Upside)
Blogger Sentiment
Bullish
RCEL Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 14.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $113.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-50.33%
12-Months-Change
Fundamentals
Return on Equity
-935.73%
Trailing 12-Months
Asset Growth
-33.81%
Trailing 12-Months
Company Description
Avita Medical
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
RCEL Company Deck
RCEL Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant achievements, including a 21% increase in commercial revenue and major clinical evidence supporting RECELL's effectiveness. Key challenges were noted in reimbursement delays impacting revenue and a lowered financial forecast. Despite the challenges, the company is optimistic about a recovery in the second half of the year and has implemented cost-saving measures.View all RCEL earnings summariesRCEL Revenue Breakdown
99.27% Commercial sales
0.67% Services for emergency preparedness
0.07% Deferred commercial revenue
RCEL Stock 12 Month Forecast
Average Price Target
$8.80
▲(67.62% Upside)
Technical Analysis
Ownership Overview
1.37% Insiders
8.55% Mutual Funds
2.96% Other Institutional Investors
78.25% Public Companies and
Individual Investors